Skip to content

Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH)

Control Study of Implantation of Enriched Bone Marrow Cells for the Treatment of Avascular Necrosis of Femoral Head

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01613612
Enrollment
60
Registered
2012-06-07
Start date
2009-03-31
Completion date
2012-12-31
Last updated
2012-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Avascular Necrosis of Femur Head

Brief summary

The purpose of this study is to compare the efficacy of autologous enriched bone marrow cell implantation combined with core decompression to single core decompression for the treatment of avascular necrosis of femoral head.

Interventions

minimal surgical invention to drill a core to the femoral head to release pressure

PROCEDUREEnriched BMCs implantation combined with core decompression

Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.

Sponsors

Guangdong Provincial People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* femoral head necrosis patients * stage I/II/III (Ficat) * age from 18 to 55 years * stop steroid treatment for minimal 6 months

Exclusion criteria

* age younger than 18 or older than 55 * any hemopathy * tumor * femoral head/neck fracture

Design outcomes

Primary

MeasureTime frameDescription
change of Visual Analogue Scalebefore invention and 24 months after inventionChange from baseline in 24 months
change of lequensne algofunctional indexbefore invention and 24 months after inventionchange from baseline in 24 months
change of WOMAC indexbefore invention and 24 months after inventionchange from baseline in 24 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026